Get the Stockscreener App
66.56
0.96%
0.6489
Cytokinetics Inc stock is traded at $66.56, with a volume of 1.42M.
It is up +0.96% in the last 24 hours and up +6.95% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$65.91
Open:
$66.55
24h Volume:
1.42M
Relative Volume:
0.75
Market Cap:
$8.20B
Revenue:
$88.04M
Net Income/Loss:
$-784.96M
P/E Ratio:
-10.19
EPS:
-6.5335
Net Cash Flow:
$-534.82M
1W Performance:
+6.66%
1M Performance:
+6.95%
6M Performance:
+19.17%
1Y Performance:
+77.45%
1-Day Range:
$65.95
$67.92
1-Week Range:
$61.67
$67.92
52-Week Range:
$29.31
$70.98
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
66.61 | 8.12B | 88.04M | -784.96M | -534.82M | -6.5335 |
VRTX
Vertex Pharmaceuticals Inc
|
447.76 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
773.48 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.50 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.01 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.83 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Dec-18-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-30-25 | Resumed | Raymond James | Mkt Perform |
| Apr-24-25 | Initiated | Barclays | Overweight |
| Feb-07-25 | Initiated | Citigroup | Buy |
| Jan-22-25 | Initiated | Stifel | Buy |
| Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-07-23 | Initiated | B. Riley Securities | Buy |
| Aug-15-23 | Initiated | SVB Securities | Outperform |
| Feb-17-23 | Initiated | BofA Securities | Neutral |
| Dec-23-22 | Reiterated | Needham | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jan-28-22 | Initiated | Goldman | Buy |
| Dec-22-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | JP Morgan | Overweight |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Feb-18-21 | Initiated | Barclays | Overweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Initiated | Goldman | Neutral |
| Jul-10-20 | Initiated | Raymond James | Strong Buy |
| May-05-20 | Initiated | Mizuho | Buy |
| Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
| Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Initiated | Morgan Stanley | Overweight |
| Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
| Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
| Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-28-16 | Reiterated | Needham | Buy |
| Nov-10-15 | Reiterated | FBR Capital | Outperform |
| Nov-09-15 | Reiterated | ROTH Capital | Buy |
| Jul-24-15 | Reiterated | MLV & Co | Buy |
| Dec-31-14 | Reiterated | ROTH Capital | Buy |
| Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
| Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
CYTK Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus
Callos, Cytokinetics EVP, sells $236k in shares - Investing.com
3,639 RSUs registered; CYTK (NASDAQ: CYTK) insider 10b5-1 sales listed - Stock Titan
Cytokinetics (CYTK) EVP sells 3,639 shares, retains 66,004 - Stock Titan
Retail Trends: Is Cytokinetics Incorporated trading at a discount2026 Summary & Low Risk Entry Point Guides - baoquankhu1.vn
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating - 富途牛牛
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Inc (HAM:KK3A) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Aug Drivers: What are the future prospects of Cytokinetics Incorporated2026 Macro Impact & Verified Entry Point Detection - baoquankhu1.vn
Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cytokinetics Inc Stock Intrinsic Values | HAM:KK3A - GuruFocus
Cytokinetics Inc (HAM:KK3A) Competitors 2026 - GuruFocus
Should you avoid Cytokinetics Incorporated stock right nowQuarterly Risk Review & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Vanguard disaggregates holdings; CYTK filings now split among subsidiaries (CYTK) - Stock Titan
Cytokinetics Inc (HAM:KK3A) Dividend - GuruFocus
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report? - Yahoo Finance
Cytokinetics Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - Barchart.com
Q3 2025 Cytokinetics Inc Earnings Call Transcript - GuruFocus
Cytokinetics (STU:KK3A) PB Ratio : (As of Mar. 26, 2026) - GuruFocus
Cytokinetics (CYTK) 10K Form and Latest SEC Filings 2026 - MarketBeat
Cytokinetics Inc (HAM:KK3A) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Aug Catalysts: What is the long term forecast for Cytokinetics Incorporated stockShort Setup & High Accuracy Trade Alerts - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK - MarketBeat
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-03-22 | Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:CYTK | Press Release - Stockhouse
Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP - MarketBeat
Cytokinetics (CYTK) EVP sells 1,930 shares, retaining over 78,000 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus
Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 By Investing.com - Investing.com Canada
Blum, Cytokinetics CEO, sells $2.2m in shares By Investing.com - Investing.com Canada
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock - MarketBeat
Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat
Malik Fady Ibraham sells Cytokinetics (CYTK) stock worth $747,850 - Investing.com
Cytokinetics Insiders Sold Shares Worth Over $3.6M - TradingView
Cytokinetics (CYTK) CFO share sale covers RSU tax obligations - Stock Titan
Mizuho Raises Price Target for Cytokinetics (CYTK) to $100 | CYT - GuruFocus
Cytokinetics (CYTK) EVP executes 8,542-share sell-to-cover for RSU taxes - Stock Titan
[Form 4] CYTOKINETICS INC Insider Trading Activity - Stock Titan
Cytokinetics President & CEO Sold Shares Worth Over $2.2M - TradingView
Cytokinetics (CYTK) CEO executes sell-to-cover stock sales for taxes - Stock Titan
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytokinetics Inc Stock (CYTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 31 '26 |
Sale |
65.00 |
3,639 |
236,535 |
66,004 |
| Lee Sung | EVP, Chief Financial Officer |
Mar 17 '26 |
Sale |
62.15 |
4,935 |
306,710 |
87,127 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 17 '26 |
Sale |
62.15 |
8,542 |
530,885 |
71,573 |
| Malik Fady Ibraham | EVP Research & Development |
Mar 17 '26 |
Sale |
62.15 |
12,033 |
747,851 |
153,902 |
| Blum Robert I | President & CEO |
Mar 17 '26 |
Sale |
62.15 |
36,601 |
2,274,752 |
430,330 |
| Callos Andrew | EVP, Chief Commercial Officer |
Mar 18 '26 |
Sale |
62.07 |
1,930 |
119,795 |
78,185 |
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):